There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC – Research Report) and AbbVie (ABBV – Research Report) with bullish sentiments.
Atricure (ATRC)
In a report released today, Michael Matson from Needham maintained a Buy rating on Atricure, with a price target of $44.00. The company’s shares closed last Wednesday at $33.70, close to its 52-week low of $32.27.
According to TipRanks.com, Matson is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atricure with a $54.86 average price target, a 56.4% upside from current levels. In a report issued on December 21, Canaccord Genuity also maintained a Buy rating on the stock with a $50.00 price target.
See today’s best-performing stocks on TipRanks >>
AbbVie (ABBV)
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie, with a price target of $197.00. The company’s shares closed last Wednesday at $160.46.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $170.33, which is a 6.1% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATRC:
